↓ Skip to main content

Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience

Overview of attention for article published in BMC Cancer, October 2018
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 X users

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
8 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience
Published in
BMC Cancer, October 2018
DOI 10.1186/s12885-018-4885-5
Pubmed ID
Authors

Roland Christian Schelker, Wolfgang Herr, Albrecht Reichle, Martin Vogelhuber

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 8 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 8 100%

Demographic breakdown

Readers by professional status Count As %
Other 2 25%
Student > Bachelor 1 13%
Student > Postgraduate 1 13%
Lecturer 1 13%
Lecturer > Senior Lecturer 1 13%
Other 0 0%
Unknown 2 25%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 2 25%
Biochemistry, Genetics and Molecular Biology 1 13%
Nursing and Health Professions 1 13%
Psychology 1 13%
Medicine and Dentistry 1 13%
Other 0 0%
Unknown 2 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 October 2018.
All research outputs
#17,993,371
of 23,108,064 outputs
Outputs from BMC Cancer
#5,010
of 8,389 outputs
Outputs of similar age
#249,742
of 349,386 outputs
Outputs of similar age from BMC Cancer
#109
of 185 outputs
Altmetric has tracked 23,108,064 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,389 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 34th percentile – i.e., 34% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 349,386 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 185 others from the same source and published within six weeks on either side of this one. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.